About 50 % of Type-1-Diabetics, 33 % Type-2-Diabetics and 75 – 80 % Mucoviscidosis patients develop exocrine pancreatic insufficiency in the course of their illness (Hardt PD, Pancreatology, 2003; Walkowiak, Journal of Pediatric Gastroenterology and Nutrition,2005).
Quantitative, fast and reliable analysis with Pancreatic Elastase ELISA from BIOSERV
Pancreatic insufficiency can easily be diagnosed by determining the concentration of pancreatic elastase in stool samples and can successfully be treated by substitution therapy.
Pancreatic Elastase ELISA (Bioserv) is perfectly suited for this analysis and can be considered as the non-invasive gold standard in the quantitative determination of pancreatic elastase in stool. It is available as 4 (Art. No. G09038) or 5 standard version (Art. No. G09040). Both versions have standards at 50, 100, 200, 500 μg/g.
The SK15 version (Art. No. G09040) includes an additional standard with a concentration of 15 μg/g. Both assays are validated for use on automated 4-plate ELISA systems.
A stool preparation set (Art. No. GZ3008) is available as accessory with prefilled stool collection tubes, which allow for fast, clean and precise sample preparation.